Mergers and acquisitions can accelerate growth, but they also carry the risk of overpaying for assets that look stronger on paper than in practice. Financial models show what a target has earned; they do not show whether its market position, customer relationships, or technology will hold up after the deal closes.

That gap is where independent market intelligence matters.

Why financial due diligence is not enough

Financial and legal reviews focus on historical performance, liabilities, contracts, and compliance. They rarely answer the commercial questions that determine whether a deal creates value:

• Is the target’s growth driven by durable demand or a temporary market condition?
• Can its offering withstand new competitors, substitute technologies, or pricing pressure?
• Are key customers likely to stay, renew, or expand after a change in ownership?
• Does the technology work at scale, and is it genuinely differentiated?
• Are the market assumptions behind the forecast realistic?

Independent intelligence complements traditional diligence by testing these assumptions before valuation and integration plans are locked in.

Three areas that need independent validation

1. Competitive positioning

A company can appear differentiated when viewed in isolation and far less so when compared with peers, new entrants, and alternative solutions.

Structured benchmarking helps acquirers assess:

• Portfolio breadth and depth.
• Technology performance and maturity.
• Geographic reach and customer base.
• Manufacturing or delivery capacity.
• Partnerships, pipeline, and regulatory progress.
• Pricing power and commercial traction.

Roots Analysis’ benchmarking services, for example, evaluate companies, products, and technologies against peer groups using defined capability metrics, including organizational strength, portfolio depth, differentiation, technology maturity, regional presence, capacity distribution, and macro-level industry forces.

The goal is not a competitor list. It is to determine whether the target holds a defensible advantage and where that advantage could erode.

2. Customer quality and revenue durability

Revenue concentration is only one part of customer risk. Acquirers also need to understand why customers chose the target, how embedded the offering is, and what could trigger a switch.

Independent research can help assess:

• Satisfaction with product performance, support, quality, and delivery.
• The role of price, technical expertise, location, capacity, and relationships in supplier selection.
• Contract duration, renewal patterns, termination clauses, exclusivity, and expansion potential.
• Whether demand is recurring, project-based, cyclical, or tied to a few programs.
• Buyer concentration and the likelihood of retention post-acquisition.

In life sciences and healthcare, this also includes clinical evidence, physician or patient adoption, payer decisions, procurement processes, and regulatory constraints.

3. Technology capability and long-term differentiation

Technology diligence should go beyond confirming that an asset works. Acquirers need to know whether it is scalable, reproducible, protected, commercially relevant, and likely to remain differentiated.

Key questions include:

• What specific problem does the technology solve, and how important is it to customers?
• How does performance compare with incumbent and emerging alternatives?
• Is the advantage supported by data, regulatory evidence, customer validation, or commercial use?
• Can it be scaled without compromising cost, quality, reliability, or compliance?
• Which patents, licenses, data rights, or know-how support defensibility?
• What investment is needed to maintain technical leadership after acquisition?
• Could a competing platform make the core offering less relevant?

Roots Analysis’ competitive-profiling work includes detailed assessments of drug, device, technology, and company portfolios, supported by public sources and targeted primary research with industry stakeholders. This helps distinguish between a genuinely differentiated capability and an attractive narrative.

From deal thesis to integration plan

Independent intelligence is most valuable when introduced early—before valuation becomes fixed and before management commits to a particular synergy story.

A practical commercial diligence process can help deal teams:

• Validate market growth outlook and revenue assumptions.
• Identify competitors, substitutes, and new entrants that could affect performance.
• Test the sustainability of customer relationships and renewal probability.
• Assess the practical value of technology, IP, pipeline, partnerships, and operational assets.
• Evaluate whether proposed synergies are achievable within the expected timeframe.
• Identify capabilities, investments, and integration priorities required after closing.
• Develop downside scenarios and risk-mitigation measures before capital is deployed.

This work also supports a broader view of the market. Roots Analysis’ M&A-tracking service, for instance, covers acquirers and targets, transaction terms, value drivers, timelines, valuations, and market trends, while also considering target-company financial, legal, and operational risks.

Better diligence supports better deals

No diligence process can remove all uncertainty from an acquisition. Markets change, competitors respond, and integration plans do not always unfold as expected. However, independent market intelligence can make the major assumptions behind a transaction more transparent and more testable.

For corporate-development leaders, the question is not simply whether a target is attractive today. It is whether the asset can retain or increase its strategic value after the acquisition, under realistic market conditions and against credible competitive scenarios.